Metsera Inc. appoints new director and legal officer

Metsera , Inc. (NASDAQ:MTSR), a pharmaceutical company with a market capitalization of $1.95 billion, announced today the appointment of Jon P. Stonehouse to its Board of Directors and Matthew Lang as Chief Legal Officer and Secretary, effective immediately. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 5.34, indicating robust short-term financial stability.

Stonehouse, with a B.S. in Microbiology from the University of Minnesota, brings extensive experience to Metsera’s board. He currently serves as CEO, President, and Interim CFO of BioCryst Pharmaceuticals (NASDAQ:BCRX) and has held senior roles at Merck (NSE:PROR) KgaA and Astra Merck/AstraZeneca. His previous board memberships include Bellicum Pharmaceuticals (OTC:BLCM) and advisory roles at Precision Biosciences and Genscript.

As part of Metsera’s Non-Employee Director Compensation Program, Stonehouse received an option grant to purchase shares of Metsera’s common stock, vesting over three years, contingent upon his ongoing service. He will also receive annual cash retainers and stock option awards.

Matthew Lang, the newly appointed Chief Legal Officer, previously served in executive positions at Lyell Immunopharma and Myovant Sciences (NYSE:MYOV), and has a background in global litigation and investigations from his time at Gilead Sciences (NASDAQ:GILD). Lang holds a B.A. from Queen’s University and a J.D. from the University of Pennsylvania Law School.

The appointments come as Metsera continues to strengthen its leadership and governance structures. The information regarding these changes is based on a press release statement.

These strategic leadership updates are part of Metsera’s ongoing commitment to corporate governance and operational excellence as the company navigates the competitive pharmaceutical industry landscape. InvestingPro analysis reveals the company maintains a FAIR financial health score, with analysts setting price targets between $38 and $56, suggesting potential upside. Discover more valuable insights and 8 additional ProTips about Metsera’s financial outlook by subscribing to InvestingPro.

In other recent news, Metsera, Inc. has awarded full annual cash bonuses to its executive officers based on the company’s performance for the year ended December 31, 2024. The bonuses, approved by the Board of Directors, reflect a 100% target achievement for each executive, with CEO Christopher Whitten Bernard receiving $241,644 and other key executives receiving varying amounts. Additionally, Cantor Fitzgerald has initiated coverage of Metsera with an Overweight rating, citing the company’s potential in the obesity drug market, particularly its lead injectable GLP-1 drug, which has shown promising Phase 2 trial results. BofA Securities also initiated coverage with a Buy rating and a $38 price target, emphasizing Metsera’s diverse portfolio in the growing obesity market. Guggenheim joined in with a Buy rating and a $56 target, highlighting Metsera’s innovative pipeline, including the ultra-long-acting NuSH analog. Furthermore, Metsera’s IPO opened 42% higher on the Nasdaq Global Select Market, with several financial firms acting as joint bookrunners for the offering. These developments indicate a strong interest and confidence in Metsera’s growth prospects within the biotechnology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.